CRISPR Licensing SCBT has recent collaboration with ERS Genomics granting access to their CRISPR/Cas9 patent portfolio, indicating openness to licensing and strategic partnerships in genome editing tools.

Mid-market Revenue With reported revenue in the 50 to 100 million range and a staff size under 200, SCBT sits in a growth-oriented mid-market segment, suggesting opportunities for scalable enterprise solutions and services tailored to mid-size biotech players.

Biotech Partnerships Active collaboration posture and a track record of licenses imply potential for co-development, technology integration, or supplier partnerships around antibodies, reagents, or research tools.

Cloud and Security Tech stack includes AWS and Mimecast, signaling a cloud-first infrastructure with security and email protection needs; opportunities exist for advanced cloud solutions, data analytics, or compliance tooling.

Talent and Growth Relatively lean employee base (51-200) combined with a collaborative, goal-oriented culture suggests needs for recruitment technology, training, HR analytics, and scalable IT/operational solutions to support expansion.